Cytotoxic Therapies Market Forecast


August 5, 2010
27 Pages - SKU: DFMN2769343
License type:
Introduction

Growth of cytotoxics will remain static over the forecast period with a CAGR of -0.1%. Several blockbuster products are due to undergo patent expiry over the forecast period and the loss of their branded sales will negatively impact on the growth of this market. But the launch of a number of drugs in rare indications will stabilize growth in this market and offset its decline from generic entry.

Reasons to Purchase
  • Quantify the performance of each of the marketed cytotoxic therapy cancer brands in the seven major markets over the period 2009 to 2019
  • Acquire a detailed account of cytotoxic therapy cancer brand dynamics and the events that drive and limit their market growth
  • Benchmark the cytotoxic therapy cancer brands against their generics and rest of class and align their 7MM performance with a rest of world snapshot
Please note: this is delivered as a Zip file.



More Oncology/Hematology reports by Datamonitor

Pipeline: Colorectal Cancer by Datamonitor
IntroductionTargeted therapies continue to dominate the colorectal cancer pipeline. With two new approvals in 2012, drug developers must now move away from anti-VEGF drugs toward ...
Pipeline: Renal Cell Cancer by Datamonitor
IntroductionSeven targeted therapies are available for the treatment of RCC but there is still considerable pipeline activity. Currently approved targeted therapies have been unable to ...
Market Forecasts: Non-Small Cell Lung Cancer by Datamonitor
Introduction This report assesses the current and future non-small cell lung cancer market across the US, Japan, France, Germany, Italy, Spain, and the UK ...
Forecast: Non-Small Cell Lung Cancer in China by Datamonitor
IntroductionPharmaceutical companies have been attracted by the high incidence of NSCLC in China and the pipeline has grown substantially. The treatment of NSCLC will continue ...
See all reports like this >>